Journal article
Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules
Elena K Schneider-Futschik, Olivia KA Paulin, Daniel Hoyer, Kade D Roberts, James Ziogas, Mark A Baker, John Karas, Jian Li, Tony Velkov
ACS INFECTIOUS DISEASES | AMER CHEMICAL SOC | Published : 2018
Abstract
The mucoid biofilm mode of growth of Pseudomonas aeruginosa ( P. aeruginosa) in the lungs of cystic fibrosis patients makes eradication of infections with antibiotic therapy very difficult. The lipopeptide antibiotics polymyxin B and colistin are currently the last-resort therapies for infections caused by multidrug-resistant P. aeruginosa. In the present study, we investigated the antibacterial activity of a series of polymyxin lipopeptides (polymyxin B, colistin, FADDI-003, octapeptin A3, and polymyxin A2) against a panel of polymyxin-susceptible and polymyxin-resistant P. aeruginosa cystic fibrosis isolates grown under planktonic or biofilm conditions in artificial sputum and their intera..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Funding Acknowledgements
J.L. and T.V. are supported by research grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01A1070896 and R01AI079330). J.L. and T.V. are also supported by the Australian National Health and Medical Research Council (NHMRC). The authors gratefully thank Dr. Simon Crawford for the help on the transmission electron microscope. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. E.K.S.-F. is the appointed Young Ambassador to Australia (American Society for Microbiology) and is supported by the Australian Postgraduate Award and the Postgraduate Publication Award.